WCG ACI Clinical, the specialty provider of independent endpoint adjudication and data monitoring committees for clinical trials, has launched the latest iteration of its proprietary AIMS (Adjudication Information Management System) platform. AIMS 4.1 offers users of WCG's endpoint adjudication solutions an enhanced interface and workflow experience.
An Endpoint Adjudication Committee is an independent group of experts that reviews clinical trial data in order to give expert opinions about clinical safety or efficacy events of interest.
Custom-built to streamline the adjudication process, the AIMS web-based platform allows global medical experts to review pre-packaged clinical trial event data and provide their expert assessment, through a single interface.
Unlike other adjudication platforms, the AIMS platform was originally designed with a simple, efficient interface for medical expert users, and helps sponsors enhance trial integrity, reduce variation in important clinical trial events and, ultimately, mitigate risk and improve patient safety in clinical trials.
"WCG ACI Clinical deeply understands expert committees and how to optimize their value in clinical programs. We understand each committee member's time is limited and valuable. That's why we designed AIMS to allow committee members to do what they do best: review global trial data, provide their expert assessments, and increase confidence in endpoint accuracy," explained Jonathan Seltzer, MD, MBA, MA, FACC, Chief Scientific Officer of WCG ACI Clinical.
Clients and committee members beta testing the newest version welcomed the enhancements:
"The latest upgrade is yet another step in WCG ACI Clinical's continuing quest to integrate scientific excellence, best practices and exceptional user experience," said Donald A. Deieso, PhD, Chairman and CEO of WCG. "By bringing together clinical expertise from its 700+ global expert community and adjudication expertise from over two decades of successful program support, WCG ACI Clinical's endpoint adjudication solutions are highly differentiated in the industry-the only model that combines specially trained adjudication staff, proprietary technology, and thoughtfully designed processes in one place."
WCG ACI Clinical's expert committee platform enables clinical development companies of all sizes to:
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.